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Superior vena cava syndrome in a 37-year-old 
woman with a cardioverter-defibrillator
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A 37-year-old woman was admitted to the cardiology department because of a clinical suspicion of superior vena cava 
(SVC) syndrome. This suspicion was based on anamnesis of decreased physical effort tolerance with recurrent facial 
and eyelid oedema, resistant to an antiallergic treatment. At the age of 16, the patient had been diagnosed as having 
hypertrophic obstructive cardiomyopathy. After one year, a dual-chamber pacemaker was implanted to decrease the 
maximum left ventricular outflow tract gradient. Sixteen years later, an implantable cardioverter-defibrillator (ICD) was 
implanted as primary sudden cardiac death (SCD) prevention due to the following risk factors: recurrent non-sustained 
ventricular tachycardia, persistent massive interventricular septum hypertrophy, and a family history of SCD. The former 
pacemaker unit was removed, but the two leads were left with distal tips localised in the right atrium and right ventricle 
and proximally cut off and secured in the area of the primary pacemaker cavity. The implantation of a dual-chamber 
ICD was complicated by pneumothorax. Next, in order to verify the diagnosis of SVC syndrome, phlebography of the 
intrathoracic venous system was performed. This confirmed the ob-
struction of both left and right subclavian vein, as well as of the SVC 
(Figs. 1,  2). This caused a collateral circulation through the thoracic 
wall venous system to develop. Additionally, all four leads of both the 
former and the current implantable devices were visualised, two of 
them being actively fixated in the right atrium and the right ventricle 
(Fig. 3). In transthoracic echocardiography, there was no thrombus visi-
ble in the right heart cavities and the echoes of hyperechogenic atrial 
and ventricular leads were visualised (Fig. 4). Due to the final diagnosis 
of SVC thrombosis, antithrombotic treatment was initiated — starting 
with a therapeutic dose of low molecular weight heparin followed by 
a vitamin K antagonist with target international normalised ratio ranged 
2.5–3.0. In conclusion, redundant leads of electrotherapy devices left in 
the venous system can generate significant health complications. Care-
ful consideration of indications for electrotherapy devices implantation 
may help prevent future complications, especially in young patients.
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Figure 1. Obstruction of the left subclavian vein 
and the ICD unit area
Figure 3. The four leads of 
both former and current  
implantable devices
Figure 2. Obstruction of the right 
subclavian vein and the superior 
vena cava
Figure 4. Hyperechogenic leads in the right atrium 
and the right ventricle
